Envista (NVST) Q2 2026 Earnings Call Transcript
Envista (NVST) reported Q2 2026 results on an earnings call, citing 5% core growth and sales of $731 million. Adjusted gross margin rose to 55.1%, adjusted EBITDA grew 28% with 14.7% margin, and adjusted EPS was $0.41 (+58%). Free cash flow was $105 million. The company raised 2026 guidance: core growth 3.5% to 4.5%, adjusted EBITDA 11% to 14%, adjusted EPS $1.50 to $1.55.
How this was made
The 30-second read
Why it matters
The key tradable item is the raised 2026 guidance range, supported by quantified Q2 operating performance (gross margin, adjusted EBITDA margin, EPS growth) and a higher free cash flow conversion rate.
Market read
Investors get a direct 2026 earnings and growth roadmap update, with margin and EPS acceleration in Q2 and explicit guidance ranges for core growth, adjusted EBITDA, and adjusted EPS.
What to watch
Brackets and wires were down high single digits due to a strong prior-year comp from pre-tariff buying, which could signal tougher comps ahead even if Spark and consumables remain strong.
Background
Envista’s Q2 2026 earnings call highlights core growth, margin expansion, free cash flow conversion, and new product launches across consumables and orthodontics.
Ticker impact
Envista raised full-year 2026 guidance, projecting core growth 3.5% to 4.5% and adjusted EPS $1.50 to $1.55 after Q2 results.
Moderately positive bias for the next few sessions as traders reprice 2026 earnings power; follow-through depends on whether margins and tax rate benefits are sustained.
The transcript discloses a specific guidance update (core growth, adjusted EBITDA, adjusted EPS) alongside quantified Q2 performance (adjusted EBITDA +28%, EPS +58%, FCF conversion 158%).
Market effects
Dental equipment and consumables demand resilience plus share gains in Spark and orthodontics could reinforce the sector’s defensive growth narrative.
Balanced growth across North America, Europe, APAC, and Latin America reduces regional concentration risk for dental suppliers.
Tariff and FX commentary (including prior-year comp effects) may influence how investors model pricing power and cost pass-through for medtech/dental peers.
Counterpoint
The guidance raise may partly reflect favorable tax-rate dynamics and one-off tariff recovery, so upside could fade if those benefits normalize.
Key entities
- companyEnvista
Dental equipment and consumables company reporting Q2 2026 results and raising full-year 2026 guidance.
- productZenSeal Pro
Bioceramic endodontic sealer described as flowable with engineered tips to reduce waste and improve access.
- productDemiPro
Cordless curing light positioned to reduce fatigue and improve access via a 360-degree rotatable tip.
- productOrmco Digital Bonding (ODB)
Digital orthodontics platform expanded to all bracket systems, aiming to solidify fixed orthodontics share.
